The oral gamma secretase inhibitor is approved as a single agent for adults with progressing desmoid tumours requiring ...

Merck KGaA's recently acquired SpringWorks unit has claimed EU approval for Ogsiveo, becoming the first approved therapy for ...

The European Commission (EC) granted marketing authorization for Ogsiveo (nirogacestat), an oral gamma secretase inhibitor, ...

Merck has announced that the European Commission has granted marketing authorisation for Ogsiveo (nirogacestat) as ...

OGSIVEO is the first and only therapy to receive marketing authorization in the EU for the treatment of desmoid ...

Ogsiveo ™ met the primary endpoint of improving progression-free survival (PFS), demonstrating a statistically significant improvement over placebo with a 71% reduction in the risk of disease ...

Corinne Jenkins has given her Buy rating due to a combination of factors surrounding the optimistic outlook for Springworks Therapeutics’s new drug, Ogsiveo. Her confidence is largely influenced ...

Confirmed objective response rate (ORR) based on RECIST v1.1 was 41% with Ogsiveo vs. 8% with placebo (p<0.001); the complete response rate was 7% in the Ogsiveo arm and 0% in the placebo arm.

Quarter in Detail Net product revenues from Ogsiveo surged 91.4% on a sequential basis to $40.2 million, driven by a strong commercial launch and high demand for the drug. Per management, Ogsiveo ...

OGSIVEO is the first and only therapy to receive marketing authorization in the EU for the treatment of desmoid tumorsSTAMFORD, Conn., Aug. 18, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc., ...